Abeona Therapeutics Company Profile (OTCMKTS:ACCP)

About Abeona Therapeutics (OTCMKTS:ACCP)

Abeona Therapeutics logoAbeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ACCP
  • CUSIP: N/A
  • Web: N/A
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Abeona Therapeutics (OTCMKTS:ACCP)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the OTCMKTS under the ticker symbol "ACCP."

Who are some of Abeona Therapeutics' key competitors?

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abeona Therapeutics stock cost?

One share of Abeona Therapeutics stock can currently be purchased for approximately $0.22.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (OTCMKTS:ACCP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Abeona Therapeutics (OTCMKTS:ACCP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Abeona Therapeutics (OTCMKTS:ACCP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Abeona Therapeutics (OTCMKTS:ACCP)
Current Year EPS Consensus Estimate: $0.70 EPS

Dividends

Dividend History for Abeona Therapeutics (OTCMKTS:ACCP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (OTCMKTS:ACCP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Abeona Therapeutics (OTCMKTS:ACCP)
Latest Headlines for Abeona Therapeutics (OTCMKTS:ACCP)
Source:
DateHeadline
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona Therapeutics Q1 revenues $186K, cash consumption $5.9M
seekingalpha.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona Therapeutics Q1 loss per share $0.13
www.reuters.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up
www.reuters.com - May 13 at 1:41 AM
nasdaq.com logoAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa
www.nasdaq.com - May 3 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces EU Orphan Drug Designation for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
www.streetinsider.com - March 8 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics announces dismissal of securities class action lawsuit
www.reuters.com - February 23 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
finance.yahoo.com - February 23 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics provides update from phase 1/2 MPS IIIA clinical trial
www.reuters.com - February 17 at 6:48 PM
finance.yahoo.com logoABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving …
finance.yahoo.com - February 10 at 3:19 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona …
finance.yahoo.com - February 8 at 8:22 PM
benzinga.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP...
www.benzinga.com - January 25 at 1:44 AM
seekingalpha.com logoPremarket analyst action - new coverage
seekingalpha.com - January 6 at 8:26 PM
streetinsider.com logoAbeona Therapeutics (ABEO) ABO-201 Program Granted Orphan Drug Designation in Europe
www.streetinsider.com - January 3 at 3:25 PM
zacks.com logoAbeona Therapeutics (ABEO): Strong Industry, Solid Earnings Estimate Revisions
www.zacks.com - January 3 at 8:14 AM
reuters.com logoBRIEF-Abeona Therapeutics receives orphan drug designation in the EU for ABO-201 gene therapy program
www.reuters.com - January 3 at 8:14 AM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Abeona Therapeutics Inc. To Contact Brower Piven Before The Lead ...
www.businesswire.com - December 30 at 1:23 AM
seekingalpha.com logoAbeona - Considerable Upside Potential With Near Term Catalysts
seekingalpha.com - December 22 at 8:18 PM
benzinga.com logoGainey McKenna & Egleston Announces A Class...
www.benzinga.com - December 17 at 1:27 AM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Abeona Therapeutics …
finance.yahoo.com - December 17 at 1:27 AM
seekingalpha.com logoAbeona slips 8% on bearish call from Mako Research
seekingalpha.com - December 12 at 3:23 PM
seekingalpha.com logoAbeona Therapeutics beats by $0.11, misses on revenue
seekingalpha.com - November 10 at 1:40 PM
seekingalpha.com logoAbeona prices 6M-share stock offering; shares ease 2%
seekingalpha.com - October 27 at 3:31 PM
finance.yahoo.com logoAbeona Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 27 at 3:31 PM
thestreet.com logoInteresting ABEO Put And Call Options For June 2017
www.thestreet.com - October 24 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Updates on ABO-102 Phase 1/2 MPS IIIA; Significant Avg. GAG Reduction Noted
www.streetinsider.com - October 20 at 3:16 PM

Social

Chart

Abeona Therapeutics (ACCP) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff